Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Human Genome Sciences (NASDAQ:HGSI.DL)

CAPS Rating: No stars

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:HGSI.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

jeffrycooks (76.52)
Submitted January 19, 2012

yes to rl

Reply | Report this Post

julianna8 (< 20)
Submitted October 05, 2010

no FDA approval

Reply | Report this Post

NASDAQ:HGSI.DL Summary

  • Sector:
    • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about HGSI.DL.

No one has written a Pitch for HGSI.DL stock yet. Tell us why you think HGSI.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in HGSI.DL.

No players have picked HGSI.DL yet. Tell us why you think HGSI.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for HGSI.DL.